Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: Results from a randomized crossover trial

Diabetes, Obesity and Metabolism

Volumn 9, Issue 3, 2007, Pages 394-407

  Lund, Søren Søgaard ^a   Tarnow, L ^a   Stehouwer, C D A ^c   Schalkwijk, C G ^c,d   Frandsen, M ^a   Smidt, U M ^a   Pedersen, O ^a,b   Parving, H H ^a,b   Vaag, A ^a,e  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Glycaemic regulation; Hypoglycaemia; Lean; Metformin; Non obese; Oral antidiabetic drugs; Oral hypoglycaemic agents; Repaglinide; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; COBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FISH OIL; FOLIC ACID; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; METFORMIN; NICOTINIC ACID DERIVATIVE; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTHRITIS; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CARDIOVASCULAR SYMPTOM; CEREBROVASCULAR ACCIDENT; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET THERAPY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG TARGETING; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INFECTION; INSULIN SENSITIVITY; LACTATE BLOOD LEVEL; LARYNX CARCINOMA; LEUKOCYTE COUNT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PARESTHESIA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; SIDE EFFECT; THROMBOCYTE COUNT; TRAFFIC ACCIDENT; WAIST CIRCUMFERENCE;

EID: 33947663556     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00713.x     Document Type: Article

References (52)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
2. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 3: 1-117.
3. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes - scientific review. JAMA 2002; 287: 360-372.
4. Consoli A, Gomis R, Halimi S et al. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: An evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 2004; 30: 509-516.
5. Skarfors ET, Selinus KI, Lithell HO. Risk factors for developing non-insulin dependent diabetes: A 10 year follow up of men in Uppsala. BMJ (Clinical research ed) 1991; 303: 755-760.
6. Dalton M, Cameron AJ, Zimmet PZ et al. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med 2003; 254: 555-563.
7. Garancini MP, Calori G, Ruotolo G et al. Prevalence of NIDDM and impaired glucose tolerance in Italy: An OGTT-based population study. Diabetologia 1995; 38: 306-313.
8. Arner P, Pollare T, Lithell H. Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 1991; 34: 483-487.
9. Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-1148.
10. Adlerberth AM, Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care 1998; 21: 539-545.
11. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721.
12. Collier A, Watson HHK, Patrick AW, Ludlam CA, Clarke BF. Effect of glycemic control metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 non-insulin-dependent diabetic patients. Diabetes Metab 1989; 15: 420-425.
13. Boyd K, Rogers C, Boreham C, Andrews WJ, Hadden DR. Insulin, glibenclamide or metformin treatment for non-insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. Diabetes Res 1992; 19: 69-76.
14. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301.
15. Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J 1977; 2: 1576-1578.
16. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract 2003; 60: 161-169.
17. Perriello G, Misericordia P, Volpi E et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928.
18. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003; 362: 1275-1281.
19. Josephkutty S, Potter JM. Comparison of tolbutamide and metformin in elderly diabetic patients. Diabet Med 1990; 7: 510-514.
20. Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetes. Diabet Med 2006; 23: 128-133.
21. Ong CR, Molyneaux LM, Constantino MI, Twigg SM, Yue DK. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006; 29: 2361-2364.
22. Massi-Benedetti M, Damsbo P. Pharmacology and clinical experience with repaglinide. Expert Opin Investig Drugs 2000; 9: 885-898.
23. Esposito K, Giugliano D, Nappo F, Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-219.
24. Dunseath GJ, Luzio SD, Cozma L, Owens DR. Dose response of repaglinide in patients with newly diagnosed type 2 diabetes: Effect on B-cell secretion. Diabetes 2002; 51: A96.
25. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-497.
26. Jovanovic L, Dailey G III, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: A 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000; 40: 49-57.
27. Metropolitan Life Insurance Company. New weight standards for men and women. Statist Bull Metrop Insur Co 1959; 40: 1-4.
28. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
29. World Health Organization. Obesity: Preventing and managing the global epidemic. WHO Technical Report Series 2000; 894: 1-253.
30. World Health Organization. Diet, nutrition and the prevention of chronic diseases. WHO Technical Report Series. Geneva, Switzerland: WHO, 2003; 916: 1-148.
31. De Jager J, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: A randomized, placebo-controlled trial. J Intern Med 2005; 257: 100-109.
32. Senn S. Cross-over Trials in Clinical Research. West Sussex, UK: John Wiley & Sons Ltd, 2002.
33. Jones B, Kenward MG. Design and Analysis of Cross-Over Trials. London, UK: Chapman & Hall, CRC, 2003.
34. Grieve A, Senn S. Estimating treatment effects in clinical crossover trials. J Biopharm Stat 1998; 8: 191-233.
35. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-278.
36. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
37. Brown H, Prescott R. Applied Mixed Models in Medicine. West Sussex, UK: John Wiley & Sons, Ltd, 2006.
38. European Medicines Agency (EMEA). Committee for medicinal products for human use (CHMP) guideline on the choice of the non-inferiority margin. European Medicines Agency (EMEA) 2005; EMEA/CPMP/EWP/2158/99: 1-11.
39. European Medicines Agency (EMEA). ICH topic E9 statistical principles for clinical trials; note for guidance on statistical principles for clinical trials. European Medicines Agency (EMEA) 1998; CPMP/ICH/363/ 96: 1-37.
40. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549.
41. Moses R, Slobodniuk R, Boyages S et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-124.
42. Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17: 1100-1109.
43. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16: 621-629.
44. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
45. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: A one-year comparison trial. Diabetes Res Clin Pract 1999; 43: 155-166.
46. Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A. Comparison between repaglinide and glipizide in type 2 diabetes mellitus: A 1-year multicentre study. Diabet Med 2001; 18: 395-401.
47. Hundal RS, Inzucchi SE. Metformin: New understandings, new uses. Drugs 2003; 63: 1879-1894.
48. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141-147.
49. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
50. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-1105.
51. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341: 427-434.
52. Yusuf S, Hawken S, Ounpuu S et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: A case-control study. Lancet 2005; 366: 1640-1649.